Moreover, given the fact that CIP2A inhibitors are commercially available, CIP2A represents a better target for breast cancer intervention compared to PP2A, because the latter has a wide range of phosphorylation function for multiple substrates and might give rise to various unnecessary side effects. The gene discussed is CIP2A; the disease is breast cancer.